TFRC and mucopolysaccharidosis type 2: Pabinafusp alfa, a BBB-penetrating and TfR-targeting antibody fusion enzyme, decreased CSF HS concentrations in patients with MPS II and exerted positive effects on neurocognitive developments in most participants (21/28) of a 52-week phase II/III clinical trial in Japan [110].